HR 1843 · in committee · significant
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
- healthcare
What this bill does
- The bill requires the FDA to tell generic drug makers whether their drugs match brand-name versions.
- Generic drug manufacturers and patients relying on generic medications are affected.
- The FDA must provide this information upon request and publish updated guidance on its comparison methods.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would requiring the FDA to disclose generic drug equivalency comparisons change the timeline and cost of bringing generic medications to market?
- 02
What specific information gaps about generic drug matching do patients and manufacturers currently face that this transparency requirement would address?
- 03
If the FDA must publish its comparison methods publicly, how might competitors or other countries use this information to their advantage?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-FL-2
Neal P. Dunn
Citizen cosponsors
0
In Congress
1/ 435
House Reps cosponsoring
Introduced 2025-03-05
Joining the bill
Legislative timeline
2025-03-05 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-03-05 · IntroReferral
Introduced in House
2025-03-05 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.